Qihan Biotechnology Co., Ltd.
A world in which cell and organ therapies are universally available to patients.
A world in which cell and organ therapies are universally available to patients.
Qihan Biotechnology Co., Ltd. is a biotechnology company with a mission to make cell and organ therapies universally accessible. Using genome-editing technology, the company develops novel cell therapies and organs for transplantation. Qihan Biotech aims to create immunologically privileged allogeneic cells and xenogeneic organs for treating cancer, organ failure, and other medical conditions. Established in 2017 and headquartered in China, the company has successfully raised three rounds of financing. Their recent Series B investment of $16.00M came from Zhejiangsheng Chanye Jijin on 22 September 2023. Qihan Biotech is advancing its cell therapy programs into IND-enabling investigations, driving towards their vision of achieving universal availability of cell and organ therapies for patients.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $16.00M | 1 | Zhejiangsheng Chanye Jijin | 22 Sep 2023 |
| Series A | $67.00M | 4 |
|
29 Mar 2021 |
| Series A | $25.50M | 5 |
|
22 Sep 2019 |
| Series A | $7.80M | - | 23 Jul 2018 |
No recent news or press coverage available for Qihan Biotechnology Co., Ltd..
We care about your data, and we'd love to use cookies make your experience better.
